BioMarin Pharmaceutical Inc.BMRNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR+46.8%
5Y CAGR+26.1%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+46.8%/yr
vs -1.8%/yr prior
5Y CAGR
+26.1%/yr
Recent acceleration
Acceleration
+48.6pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
3.2x
Strong expansion
Streak
4 yr
Consecutive growthAccelerating
PeriodValue
202526.56%
202413.07%
20238.41%
20228.40%
20212.94%
20208.34%
201912.66%
20189.03%
201716.31%
201618.48%